ATHERTON, Calif.--(BUSINESS WIRE)--WellTheory, a first-of-its-kind virtual solution for the 50 million Americans suffering with autoimmune disease, launched an enterprise solution today that will enable employers and payers to offer autoimmune care through WellTheory. Autoimmune disease is often a top area of spend for employers and payers, but typically flies under the radar due to the invisibility of these illnesses both within the workplace and in claims data. Employers and health plans spend, on average, four times more on patients with autoimmune diseases than the average member. Through its new enterprise solution, WellTheory will tackle the hidden costs and productivity impacts of untreated autoimmune diseases head on — across the entire healthcare ecosystem.
It typically takes 4.5 years and 5 different doctors to reach an autoimmune diagnosis in America. It’s a journey that is long, physically and emotionally painful, and expensive. WellTheory is committed to bridging the glaring gaps in the standard of care for autoimmune patients today and uncovering solutions for this underserved community. Over the past 30 years, the prevalence of autoimmune diseases has more than doubled, disproportionately impacting women who make up 80 percent of patients. WellTheory is on a mission to reverse the autoimmune epidemic, and access to cost-effective autoimmune care is how they’re doing it.
“The need for affordable and effective autoimmune care has never been greater — invisible illnesses affect 15 percent of the workforce with 78 percent of full-time workers reporting that their job performance has suffered as a result. Not to mention the staggering costs for self-funded employers and payers alike, driven in large part by skyrocketing pharmacy costs for these patients,” said Ellen Rudolph, Co-Founder and CEO of WellTheory. “Since our inception, we’ve been on a mission to transform the way autoimmune disease is treated, and we’re thrilled to share a major milestone in WellTheory’s journey by launching an enterprise solution.”
WellTheory’s proprietary care model is built on over a decade of clinical evidence and has demonstrated an ability to support clinical remission and lower usage of high-cost medications in peer-reviewed published papers. The platform provides whole-body care that addresses the underlying causes of autoimmunity and supports individuals no matter where they are in their autoimmune journey.
Since launching its direct-to-consumer solution, WellTheory has achieved transformative outcomes including: 85 percent improvement reduction in fatigue, 53 percent reduction of pain, and 74 percent increase in general life satisfaction within 20 weeks; 85 percent decrease in ER and urgent care visits within 16 weeks; 43 percent reduction in unnecessary specialty and visits and outpatient care within 16 weeks; and more than $11,000 estimated annual savings per member on biologics.
WellTheory’s all-in-one enterprise solution is tailored to the unique needs of health plans, employers, businesses, employees, and members to drive outcomes and reduce costs at scale. It seamlessly integrates into an enterprise’s existing ecosystem and embeds within their network of providers, carriers, and other benefits to support a streamlined member experience.
To learn more about WellTheory’s enterprise offering, visit https://www.welltheory.com/for-businesses
ABOUT WELLTHEORY:
WellTheory is a virtual care platform reversing the autoimmune epidemic by filling the gaps left behind in traditional healthcare. WellTheory offers a research-backed proprietary program that addresses the root cause of autoimmunity and treats the whole person with the aim to reduce symptoms, improve quality of life, and lower costs. WellTheory’s platform centers around evidence-based, high-touch care led by an interdisciplinary team of autoimmune experts, including licensed registered dietitians and board-certified health coaches. It’s an anti-symptom-masking model that goes beyond the pill, built by autoimmune patients and validated by decades of clinical research.
